SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center
| Autor: | Luciana Kase Tanno, Pascal Demoly, Etienne Beaudoin, Frédéric Bérard, Alain Didier |
|---|---|
| Přispěvatelé: | Herrada, Anthony, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Allergy Coronavirus disease 2019 (COVID-19) MESH: Covid-19 MESH: Hypersensitivity Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Context (language use) Review 03 medical and health sciences [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Intervention (counseling) vaccine Drug Discovery Pandemic medicine anaphylaxis Pharmacology (medical) 030212 general & internal medicine [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases Pharmacology [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases MESH: Drug hypersensitivity business.industry COVID-19 medicine.disease allergy MESH: Anaphylaxis MESH: France Vaccination Infectious Diseases SARS-CoV-2 vaccination 030228 respiratory system [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie Family medicine recommendations [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Medicine [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie MESH: Covid-19 Vaccines [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology business [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology Anaphylaxis |
| Zdroj: | Vaccines Vaccines, Vol 9, Iss 560, p 560 (2021) Vaccines, 2021, 9 (6), pp.560. ⟨10.3390/vaccines9060560⟩ |
| ISSN: | 2076-393X |
| DOI: | 10.3390/vaccines9060560⟩ |
| Popis: | International audience; Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|